Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024 Oct 24, 2024 07:08AM
Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences Aug 27, 2024 07:00AM
Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024 Jul 24, 2024 07:00AM
Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression Jun 13, 2024 07:00AM
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update May 14, 2024 07:30AM
View Older Stories

May 7, 2024 09:00AM Syros to Participate in Upcoming Investor Conferences
May 7, 2024 07:00AM Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
Apr 9, 2024 07:07AM Syros Pharmaceuticals (SYRS) Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
Apr 9, 2024 07:00AM Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
Apr 2, 2024 04:30PM Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 27, 2024 07:30AM Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
Mar 25, 2024 07:03AM Syros Pharmaceuticals (SYRS) Completes Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
Mar 25, 2024 07:00AM Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
Mar 20, 2024 07:00AM Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
Feb 27, 2024 07:00AM Syros to Participate in TD Cowen 44th Annual Health Care Conference
Jan 8, 2024 07:00AM Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene
Dec 6, 2023 07:03AM Syros Pharmaceuticals (SYRS) Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
Dec 6, 2023 07:00AM Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
Nov 21, 2023 07:30AM Syros to Participate in Upcoming Investor Conferences
Nov 14, 2023 07:30AM Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
Nov 7, 2023 07:30AM Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
Oct 2, 2023 08:45AM Syros Pharmaceuticals (SYRS) Announces Planned CEO Leadership Transition and Strategic Reorganization
Oct 2, 2023 08:45AM Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company
Sep 7, 2023 04:30PM Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 8, 2023 07:30AM Syros Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
Aug 4, 2023 04:30PM Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 1, 2023 07:30AM Syros to Report Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
Jul 5, 2023 04:30PM Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 8, 2023 07:30AM Syros to Present at Sidoti June 2023 Virtual Small-Cap Conference
Jun 1, 2023 04:30PM Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 25, 2023 05:07PM Syros Pharmaceuticals (SYRS) Presents Data from Phase 1/1b Clinical Trial of SY-5609
May 25, 2023 05:05PM Syros Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting
May 10, 2023 07:30AM Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update
May 9, 2023 07:00AM Syros to Present at JMP Securities 2023 Life Sciences Conference
May 2, 2023 07:00AM Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 2, 2023 07:30AM Syros Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
Feb 28, 2023 07:30AM Syros to Participate in Upcoming Investor Conferences in March
Feb 23, 2023 07:30AM Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023
Feb 9, 2023 04:05PM Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 26, 2023 07:05AM Syros Pharmaceuticals (SYRS) Granted FDA Fast Track Designation for Tamibarotene
Jan 26, 2023 07:00AM Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome
Jan 9, 2023 07:00AM Syros Announces Clinical Updates and 2023 Strategic Priorities
Dec 23, 2022 04:05PM Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 12, 2022 07:32AM Syros Pharmaceuticals (SYRS) Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in A
Dec 12, 2022 07:30AM Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and
Dec 10, 2022 10:00AM Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial
Dec 5, 2022 07:00AM Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10
Nov 22, 2022 07:30AM Syros to Participate at Piper Sandler 34th Annual Healthcare Conference
Nov 14, 2022 07:30AM Syros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
Nov 7, 2022 07:30AM Syros to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
Nov 4, 2022 04:30PM Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 3, 2022 09:01AM Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting
Oct 5, 2022 04:01PM Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 16, 2022 04:05PM Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement
Sep 15, 2022 04:13PM Syros and Tyme Technologies Announce Stockholder Approval of Merger
View Older Stories